SAC's Alleged Insider Trade Hid in Dark Pools
NEW YORK (TheStreet) - U.S. Attorney Preet Bharara may have hooked his biggest insider trade, after unveiling new allegations against a SAC Capital Management trader that raises the prospect the worst is yet to come for the hedge fund and its founder Steven A. Cohen.
But as prosecutors untangle a web of fraud that's so far ensnarled scores of Wall Streeters and industry heavyweights like former McKinsey & Co. head and Goldman Sachs(GS) director Rajat Gupta and Galleon Group founder Raj Rajaratnam, the implications of Bharara's newest allegations may extend far beyond SAC Capital and its highly watched head.
Details of a Tuesday charge laid out against a former SAC trader raises the prospect that the rise of algorithmic trading and so-called 'dark pools' are facilitating insider hedge fund trading. Were the U.S. Attorney's newest charge to be borne out, algorithmic and dark pool trading will be at the heart of the insider trading conspiracy.
It would also be an indication of the work left for the Securities and Exchange Commission to gain a grip over increasingly opaque stock trading venues, which have been considered at the heart of a May 2010 market meltdown and various subsequent 'flash crashes.'
The U.S. attorney's charge alleges that former SAC trader Mathew Martoma was able to make $276 million in profit and avoided losses on the shares of Elan(ELN) and Wyeth by way of trading on illegal knowledge of negative trials in an Alzheimer's drug being developed by both companies. While allegations do not mention Cohen by name, they repeatedly refer to a "Hedge Fund Owner" as receiving Martoma's advice to sell shares and instructing the hedge fund to liquidate large blocks of stock.
In Martoma's alleged fraud, algorithmic trading and dark pools appear to have played a key role in obscuring what the U.S. Attorney says is the biggest insider trading profit in U.S. history for years.
According to the U.S. Attorney, after receiving a tip that pharmaceuticals Elan and Wyeth would soon disclose negative Alzheimer drug trials tests in late July 2008, Martoma is alleged to have told SAC's owner to liquidate the fund's position in both company's shares.